Yellow fever resurgence: An avoidable crisis?

Nicole P Lindsey^{1

2}, Jennifer Horton^{3

4}, Alan D T Barrett^{3

5}, Maurice Demanou^{3

6}, Thomas P Monath^{3

7}, Oyewale Tomori^{3

8}, Michel Van Herp^{3

9}, Herve Zeller^{3

10}, Ibrahima Soce Fall¹¹, Laurence Cibrelus^{3

4}, J Erin Staples^{3

12}

Affiliations

¹ Eliminate Yellow Fever Epidemic Risk Assessment Working Group, Geneva, Switzerland. frd3@cdc.gov.
² Arboviral Diseases Branch, U.S. Centers for Disease Control and Prevention, Fort Collins, CO, USA. frd3@cdc.gov.
³ Eliminate Yellow Fever Epidemic Risk Assessment Working Group, Geneva, Switzerland.
⁴ Eliminate Yellow Fever Epidemics Strategy, High Impact Epidemics, WHO Health Emergencies Programme, World Health Organization, Geneva, Switzerland.
⁵ Department of Pathology and Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.
⁶ Regional Office for Africa, World Health Organization, Ouagadougou, Burkina Faso.
⁷ Crozet BioPharma, Lexington, MA, USA.
⁸ African Center for Genomics of Infectious Diseases (ACEGID), Redeemer's University, Ede, Nigeria.
⁹ Médecins Sans Frontières, Brussels, Belgium.
¹⁰ Consultant, Paris, France.
¹¹ WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.
¹² Arboviral Diseases Branch, U.S. Centers for Disease Control and Prevention, Fort Collins, CO, USA.

Nicole P Lindsey et al. NPJ Vaccines. 2022.

. 2022 Nov 2;7(1):137.

doi: 10.1038/s41541-022-00552-3.

¹ Eliminate Yellow Fever Epidemic Risk Assessment Working Group, Geneva, Switzerland. frd3@cdc.gov.
² Arboviral Diseases Branch, U.S. Centers for Disease Control and Prevention, Fort Collins, CO, USA. frd3@cdc.gov.
³ Eliminate Yellow Fever Epidemic Risk Assessment Working Group, Geneva, Switzerland.
⁴ Eliminate Yellow Fever Epidemics Strategy, High Impact Epidemics, WHO Health Emergencies Programme, World Health Organization, Geneva, Switzerland.
⁵ Department of Pathology and Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.
⁶ Regional Office for Africa, World Health Organization, Ouagadougou, Burkina Faso.
⁷ Crozet BioPharma, Lexington, MA, USA.
⁸ African Center for Genomics of Infectious Diseases (ACEGID), Redeemer's University, Ede, Nigeria.
⁹ Médecins Sans Frontières, Brussels, Belgium.
¹⁰ Consultant, Paris, France.
¹¹ WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.
¹² Arboviral Diseases Branch, U.S. Centers for Disease Control and Prevention, Fort Collins, CO, USA.

No abstract available

Conflict of interest statement

N.P.L., J.H., T.M., M.D., O.T., M.V.H., H.Z., L.C., and J.E.S. declare no competing interests. A.D.T.B. is Editor-in-Chief of npj Vaccines.

1. World Health Organization. Eliminate Yellow fever Epidemics (EYE): a global strategy, 2017–2026. Wkly Epidemiol. Rec. 2017;92:193–204. - PubMed
1. Gaythorpe KA, et al. The global burden of yellow fever. eLife. 2021;10:e64670. doi: 10.7554/eLife.64670. - DOI - PMC - PubMed
1. World Health Organization. Epidemic focus: yellow fever. Wkly Epidemiol. Rec. 2017;91:217–218.
1. Vasconcelos P. F., Monath T. P. Yellow fever remains a potential threat to public health. Vector-Borne and Zoonotic Diseases. 16. Published Online: 10.1089/vbz.2016.2031 (2016). - PubMed
1. Situation report: yellow fever, 28 October 2016. Geneva: World Health Organization. Available at: http://apps.who.int/iris/bitstream/10665/250661/1/yellowfeversitrep28Oct...).